News
IFRX
1.060
+0.95%
0.010
Weekly Report: what happened at IFRX last week (0407-0411)?
Weekly Report · 6d ago
Weekly Report: what happened at IFRX last week (0331-0404)?
Weekly Report · 04/07 09:19
InflaRx N.V. Announces 2025 Annual General Meeting Agenda
TipRanks · 04/03 11:57
InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
TipRanks · 03/31 10:16
Weekly Report: what happened at IFRX last week (0324-0328)?
Weekly Report · 03/31 09:21
Carnival To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Wednesday
Benzinga · 03/26 16:26
InflaRx Price Target Raised to $10.00/Share From $7.00 by Guggenheim
Dow Jones · 03/26 13:48
Guggenheim Maintains Buy on InflaRx, Raises Price Target to $10
Benzinga · 03/26 13:38
InflaRx price target raised to $10 from $7 at Guggenheim
TipRanks · 03/26 11:06
Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX), Eli Lilly & Co (LLY) and Incyte (INCY)
TipRanks · 03/25 00:40
Weekly Report: what happened at IFRX last week (0317-0321)?
Weekly Report · 03/24 09:19
LifeSci Capital Remains a Hold on InflaRx (IFRX)
TipRanks · 03/21 20:25
InflaRx Price Target Maintained With a $8.00/Share by HC Wainwright & Co.
Dow Jones · 03/21 11:38
HC Wainwright & Co. Reiterates Buy on InflaRx, Maintains $8 Price Target
Benzinga · 03/21 11:28
Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential
TipRanks · 03/21 10:36
InflaRx N.V. Reports 2024 Results and Key Achievements
TipRanks · 03/21 04:07
InflaRx GAAP EPS of -€0.78, revenue of €0.17M
Seeking Alpha · 03/20 11:34
Earnings Scheduled For March 20, 2025
Benzinga · 03/20 08:32
Here's the major earnings before the open tomorrow
Seeking Alpha · 03/19 22:00
InflaRx Q4 2024 Earnings Preview
Seeking Alpha · 03/19 19:10
More
Webull provides a variety of real-time IFRX stock news. You can receive the latest news about Inflarx through multiple platforms. This information may help you make smarter investment decisions.
About IFRX
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.